FTC challenges more than 100 pharma patents

09-11-2023

Muireann Bolger

FTC challenges more than 100 pharma patents

Paul Brady Photography / Shutterstock.com

Commission targets big pharma companies over ‘improper listings’ | Agency argues that alleged inaccuracies may delay lower-cost generic drug competition, stall drug development, and stifle innovation.


FTC, Lina Khan, patents, AbbVie, AstraZeneca, Boehringer Ingelheim, Impax Laboratories, Kaleo, Mylan, Glaxo-Smith Kline, Teva, Orange Book.

LSIPR